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Abstract
Introduction—Genetic-guided selection of non-oncologic medications is not commonly 
practiced in general, and at University of California, San Francisco (UCSF) Health, specifically. 
Understanding the unique position of clinicians with respect to clinical pharmacogenetics (PG) at 
a specific institution or practice is fundamental for implementing a successful PG consult service.
Objectives—To assess clinicians’ current practices, needs, and interests with respect to clinical 
PG at UCSF Health, a large tertiary academic medical center.
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Methods—A list of 42 target medications with clinical PG recommendations was complied. 
Clinical specialties that routinely used the target medications were identified. A 12-question 
survey focused on practice of PG for target medications was developed. Pharmacists and 
physicians were surveyed anonymously in several clinical specialties. Survey results were 
analyzed using descriptive statistics.
Results—Of the 396 clinicians surveyed, 76 physicians and 59 pharmacists participated, 
resulting in 27% and 50% average response rates, respectively. The current use of PG in clinical 
practice for physicians and pharmacists was 29% and 32%, respectively, however this number 
varied across clinical specialties from 0% to 80%. Of clinicians whom reported they do not 
currently apply PG, 63% of physicians and 54% of pharmacists expressed interest in integrating 
PG. However, the level of interest varied from 20% to 100% across specialties. Of the respondents, 
64% of physicians and 56% of pharmacists elected to provide contact information to investigators 
to further discuss their interest related to clinical PG.
Conclusions—While PG is not uniformly practiced at UCSF Health, there is considerable 
interest in utilizing PG by the respondents. Our approach was successful at identifying clinicians 
and services interested in PG for specific drug-gene pairs. This work has set a foundation for next 
steps to advance PG integration at UCSF Health. Clinicians can adopt our approach as preliminary 
work to build a clinical PG program at their institutions.
Keywords
Pharmacogenetics; genetic testing; clinical pharmacy service; pharmacists; physicians; surveys 
and questionnaires
There are well over 200 medications, oncologic and non-oncologic, with inherited 
pharmacogenetic (PG) biomarkers discussed in their official United States (US) Food and 
Drug Administration approved package inserts.(1) Of these, at least 49 medications have 
specific dosing guidelines established by expert panels in both the US (Clinical 
Pharmacogenetic Implementation Consortium [CPIC])(2) and Europe (Royal Dutch 
Association for the Advancement of Pharmacy – Pharmacogenetics Working Group 
[DPWG]).(3) Despite the availability of translational data necessary for clinical 
implementation, clinicians in the US do not routinely practice PG.(4, 5) There are only a 
handful of large research based institutions across the country with organized and 
centralized clinical PG programs.(6–11) While a seemingly obvious theoretical framework 
for the implementation of PG is easy to discuss, the practical steps necessary for integrating 
PG into routine clinical practice are challenging.
Scientific, financial, regulatory, ethical, and process challenges to clinical implementation of 
PG exist, with limited or lack of payer reimbursement (4, 12) prominent among them. Other 
specific challenges include limited education of clinicians, slow turnaround time of PG 
testing, inadequate electronic clinical decision support tools, ineffective integration of PG 
into the electronic health record (EHR), and limited or lack of cost-effectiveness and clinical 
utility data in support of PG.(2, 12–18) While these barriers are a general representation of 
the field of clinical PG, they may not equally contribute to lack or limited practice of PG at 
specific institutions across the US. For example, for clinicians at Vanderbilt University, 
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electronic decision support may not be a barrier, given that they have an extensive system in 
place.(10) Similarly, at the University of Chicago, preemptive genotyping of patients prior to 
the acute need for treatment is used to overcome the barrier associated with slow turnaround 
time of PG tests.(9) Thus for any institution interested in initiating a PG program, it is 
important to assess (i.e., “personalize”) the current climate of that institution with respect to 
PG.
While numerous published studies focus on knowledge and attitudes of clinicians on clinical 
PG,(5, 17–19) there is a gap in approach for assessment of current practices, needs, and 
interests of clinicians about clinical PG across specialties. A current assessment of needs and 
interests of clinicians and an understanding of challenges to the routine application of PG 
testing across services is essential to integrating PG as a standard of care in general, and at 
University of California, San Francisco (UCSF) Health, specifically.
The overarching goal of this exploratory study was to better understand current practice 
surrounding clinical PG in a large tertiary medical center and to identify clinical faculty with 
a specific interest in the application of PG in their practice (PG Champions). The primary 
objective of this study was to develop and implement a systematic process and validated 
survey tool to identify current practices, needs, and interests of clinicians at a large tertiary 
medical center.
Methods
Study Design
This is a cross-sectional, exploratory, and qualitative study of clinicians at UCSF Health to 
determine their current practices and needs related to clinical PG.
Medication Selection for Clinician’s Needs Assessment
A list of medications with actionable PG data supported by a strong level of 
recommendation for drug-gene interactions based on clinical guidelines published by the 
CPIC and the DPWG as of November 2016 was assembled. Next, we identified the 
utilization of our targeted medications over a finite period (January 2015 – September 2016) 
at UCSF Health. To be sure that all of these medications were prescribed by providers at 
UCSF Heath, for each medication on this list, counts of orders, counts of administration 
(inpatient only), and counts of distinct patient encounters were extracted for inpatient and 
outpatient from Epic, the UCSF Health EHR system (called APeX at UCSF Health). The 
clinicians in the team discussed each medication for inclusion in the survey.
Target Services for Needs Assessment
The target medications selected for the needs assessment were the basis for identifying 
clinical services that would commonly prescribe these medications. These services were 
selected based on discussion with clinicians in our team. The following eight services were 
the target of the needs assessment survey: 1) cardiology, 2) psychiatry, 3) pain management, 
4) infectious diseases, 5) oncology, 6) transplant (solid and bone marrow), 7) neurology, and 
8) primary care (i.e., internal medicine and family practice).
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Survey Development
A 12-question survey was developed to assess clinicians’ current practices related to PG or 
interest in integrating PG into their practice at UCSF Health (Appendix I). Specifically, the 
survey included three questions about clinician and practice history (i.e., degree[s] 
completed, number of years in practice, and area of practice[s]; note: a clinician could select 
more than one area of practice), followed by a fourth question that specifically asked if they 
have used PG in their practice within the past 12 months. Clinicians who responded “yes” to 
question 4 were then presented in questions 5 and 6 with drug-gene pairs populated based on 
their response to question 3, and asked to identify drug-gene interaction(s) used in the past 
12 months and frequency of use (in question 5) and drug-gene interaction(s) that they would 
like to add to their service, respectively. In both questions 5 and 6, clinicians had the 
opportunity to add drug-gene interaction(s) not listed in the choices provided. Clinicians, 
who responded “no” to question 4, were then directed to question 7, where they were asked 
if they would like to integrate PG into their clinical practice. A “yes” response for question 7 
led to question 8, where clinicians were presented with drug-gene pair(s) most appropriate 
for their area of practice that they could select to add to their clinical service. The clinicians 
also had the opportunity to free-text drug-gene interactions that were not available in the 
choices provided, but that they were interested in adding to their clinical practice.
While the survey participants could choose to remain anonymous, given our ultimate project 
goal of initiation of a clinical PG service, it was important to determine clinical services and 
practitioners currently using or interested in using PG in their current practice. As such, all 
clinicians in question 9 of the survey were given an opportunity to provide their name, 
service, and preferred method of contact as an option. Clinicians who completed question 9 
were entered into a raffle to win one of three iPad minis. Regardless of their response to 
questions 1 through 9, all clinicians were asked to respond to questions 10, 11, and 12. In 
question 10, clinicians were asked to select from a list of barriers to clinical PG for their 
practice, including “no barriers”. In question 11, clinicians were asked if observational 
studies in support of clinical PG were sufficient evidence for making a decision related to 
PG. Question 12 was a free-text response where clinicians had an opportunity to provide any 
additional comments on this survey and its goal.
PGPG
Survey Validation—The survey questions were assessed for their clarity and 
dependability by having them reviewed and piloted by physicians (N=4) and pharmacists 
(N=8) at UCSF Health who were not part of the study population.
Study Population—A Qualtrics™ (www.qualtrics.com)-based survey platform was used 
to disseminate and collect the survey data. It is important to acknowledge that our survey can 
be administered to all health care providers involved in making decisions related to the use 
of medications. At our institution, PG-guided prescribing is most likely to be performed by 
either a physician or clinical pharmacist. Therefore, only physicians and pharmacists in 
targeted specialty services were invited to participate in the survey. To ensure widespread 
dissemination, we obtained the support of the chief medical officer and the director of 
pharmacy at UCSF Health. The chief medical officer provided the names of department 
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heads to contact for survey dissemination within the different targeted specialties. The UCSF 
Committee on Human Subjects Research approved this study and clinicians’ consent was 
obtained prior to survey participation.
Physician Recruitment—A link to the survey was emailed to the head of nine 
departments. The department heads were given the following three options. First, to have the 
head of the department directly redistribute the sent email containing the Qualtrics link to 
physicians in their department. Second, to provide the email list of physicians in the 
department to the principal investigator (PI) to email the survey to them directly. The third 
option was to have a department group meeting with investigators to introduce the survey 
prior to emailing the link.
Pharmacist Recruitment—The department chair of Clinical Pharmacy in the UCSF 
School of Pharmacy and director of Pharmaceutical Services at UCSF Health were asked to 
help with dissemination of the survey to pharmacists at UCSF Health. They were provided 
with the same options listed above for survey distribution.
Data Analysis—The survey response data were exported to Microsoft® Excel (Microsoft 
Corporation, Redmond, Washington) for analysis. Contingency tables were created for 
descriptive statistical analysis of participant demographics and responses to survey 
questions. All data were summarized by descriptive statistics for physicians and pharmacists 
separately,
Results
Medication Selection
A list of 49 medications with actionable PG data supported by a strong level of 
recommendation for drug-gene interactions based on clinical guidelines published by the 
CPIC and the DPWG as of November 2016 was assembled (Supplementary Table 1). Of 
these 49 medications, 7 medications were excluded from the survey either because the 
medication was not prescribed at UCSF Health in 2015 and 2016 (e.g., boceprevir and 
trimipramine), shifting clinical guidelines limited their use (i.e., peginterferon: 28 patients in 
2016; ribavirin: 15 patients in 2016; thioguanine: 7 patients in 2016) and clinical judgment 
of our team (i.e., metoprolol, haloperidol, carvedilol).
Survey Distribution
Surveys were sent to 396 clinicians (277 physicians and 119 pharmacists) from January 
2017 to June 2017 (Figure 1). The process of reaching the clinicians across different services 
was not uniform and differed by service. Family practice requested more guidance on PG 
testing practice prior to sending the survey link out to clinicians in that service and a brief 
document summarizing CPIC guidelines on medications commonly used in that service was 
provided to physicians. Two of the provider groups, cardiology and family practice, 
preferred the PI to introduce the survey to clinicians via a short presentation followed by a 
question and answer session at their department faculty meeting. For all other departments 
(n=7), the department head or division chief distributed the survey link through a survey 
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introduction email. The survey link was sent to all physicians within a department a 
maximum of three times over the study period.
The survey was distributed to the pharmacists by providing the link for the survey along with 
introductory information in two separate issues of a weekly newsletter from the office of the 
director of Pharmaceutical Services at UCSF Medical Center to pharmacists. Additionally, 
the PI was invited to present at a UCSF Health pharmacy managers’ meeting on two 
occasions prior to distribution of the newsletter.
Survey Results
Of the 396 clinicians to whom a link for the survey was provided, we received 166 
responses, of which 135 were complete (Figure 1). A total of 76 physicians and 59 
pharmacists completed the survey yielding 27% and 50% response rates, respectively. The 
number of years in practice for physicians varied, with the majority of physicians (64%) 
being in practice over 10 years, while 32% of pharmacists had a practice history of over 10 
years (Table 1).
The current reported use of PG testing in clinical practice for physicians and pharmacists 
was 29% and 32%, respectively (Table 1), however this number varied across services from 
0% to 80% (Table 2). Of the clinicians who reported they were not currently using PG in 
their practice, on average, 63% of physicians and 54% of pharmacists were interested in 
integrating PG testing into their practice, however their interest varied from a low of 20% 
(i.e., infectious diseases) to a high of 100% (i.e., cardiology) (Table 2). For example, of eight 
cardiologists who completed the survey, none reported current use of PG in their practice; 
however, all were interested in starting PG testing for their practice (Table 2). More than half 
of the survey respondents (64% of physicians and 56% of pharmacists) self-identified and 
provided contact information to further discuss their interest related to clinical PG for their 
service. On average, 59% of physicians and pharmacists were comfortable with evidence 
obtained through observational studies in support of clinical PG; however, this number 
varied across services and professions (Table 2). For example, while all cardiologists who 
completed the survey were interested in clinical PG, only half would consider observational 
studies as sufficient evidence for integration of PG. However, PG evidence from 
observational study was sufficient for all oncologists.
Table 3 summarizes the responses received from eight services for clinicians who currently 
(within the last 12 months) use PG-based prescribing and clinicians who are not currently 
using PG but are interested in integrating PG testing for specific drugs-gene pairs. Several 
agents, such as warfarin or simvastatin, were included in the list of medications for more 
than one service while others, like phenytoin, were only included in one survey from a 
neurology service. Current use and interest in specific drug-gene pairs varied across 
services. For example, none of the cardiologists and primary care physicians reported use of 
PG for guiding initial warfarin dosing in the past 12 months, but 1 of 4 neurologists reports 
having used PG to guide warfarin dosing in the past 12 months. However, 38% (n=3) of 
cardiologists and 50% (n=8) of primary care physicians were interested in integrating 
warfarin PG in their practice while none of the 3 remaining neurologists were interested in 
integrating warfarin PG in their practice.
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Tacrolimus-CYP3A5 and voriconazole-CYP2C19 appear to be the most commonly used 
drug-gene pair by pharmacists in the past 12 months with 31% and 33% of pharmacists 
having reported the use of PG for these medications, respectively (Table 3). In the physician 
group, the most commonly used drug-gene pair was mercaptopurine/azathioprine-TPMT 
with 67% (n=6) of oncologists having reported current use of this PG test. It is clear from 
these data, with the exception of a few medications in certain services (e.g., warfarin and 
neurology), that there is interest in integrating PG into clinical practice for most medications 
on this list by clinicians across services.
Table 4 reports the barriers identified by clinicians in this survey for adoption of PG. The 
most common barriers (i.e., identified by more than 50% of clinicians) reported by 
physicians and pharmacists for integrating PG are a lack of established and clear guidelines/
protocols for translating test results (68%), limited professional education in PG (59%), and 
cost/payer restrictions on reimbursement for PG testing (59%).
Discussion
Given the potential benefits of reducing cost and adverse outcomes, there is a shortage of 
organized translation of PG research to clinical practice in general,(4) and at UCSF Health, 
specifically. This lack of routine clinical application may contribute to suboptimal treatment 
outcomes. To overcome this challenge, our goal is to develop a service that facilitates 
seamless integration of PG into clinical practice. The first step towards this goal is to obtain 
a deeper understanding of current practices, needs, interests, and challenges of clinicians 
about PG. A survey of clinicians across services provided valuable insight on current 
clinician practices and needs about PG. This information is instrumental in developing a 
system for organized translation of this science. Indeed, our results indicate that despite the 
existence of considerable interest in using PG in clinical practice, it is not optimally 
integrated and uniformly practiced across services. Importantly, given the diverse interest of 
clinicians for PG testing, the work presented in this study is leading to development of an 
array-based PG testing capability at UCSF Health.
While numerous published studies focus on knowledge and attitudes of clinicians on clinical 
PG (5, 17–19), this study focused primarily on PG in clinical practice. To our knowledge, 
the questions related to clinician needs, practices, and interests have not previously been 
reported in general, and certainly not for UCSF Health. This study uniquely engaged both 
physicians and pharmacists within UCSF Health to gain insight about their practice needs 
and interests related to specific drug-gene combinations across specialties.
The bioinformatics and non-bioinformatics challenges limiting widespread use of clinical 
PG in practice reported by clinicians at UCSF Health are not novel.(2, 12, 20–22) However, 
an important limitation, often not documented in literature, is related to the level of evidence 
that clinicians feel is needed for clinical application of PG. Given that the majority of 
recommendations published to date related to clinical PG are driven from observational 
studies, some clinicians see that as insufficient evidence. While a discussion related to level 
of evidence for practice of clinical PG is beyond the scope of this paper, all efforts targeted 
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towards initiation of such services should determine the willingness of both pharmacists and 
physicians to adopt PG based on evidence from observational studies.
There are limitations with our approach that need to be acknowledged. First, there was a 
potential of sampling bias. Although the majority of participants received the survey through 
an email link, two groups (cardiologists and family practice physicians) received an in 
person introduction to the survey before it was sent to the team. However, given that the 
response rate for these services was similar to other services, sampling bias does not appear 
to have affected these results. Second, calculation of the survey response rate was subject to 
several limitations. First, the investigators were not in control of whom the survey was sent 
to, and as such, it was challenging to determine the response rate. Furthermore, the use of 
email lists may not have included the current group of clinicians in a service. Finally, the 
overall survey response rate among the physicians and pharmacists is considered below the 
desired 60% threshold.(23) Survey fatigue of clinicians in a large medical center may have 
contributed to low response rates and increasing risk of participation bias or non-response 
bias. We attempted to compensate for survey fatigue by focusing the survey on current 
practices and limiting the number of questions such that a clinician could complete the 
survey in less than 10 minutes.
Despite these limitations, we have learned a significant amount about current practices and 
interests of physicians and pharmacists across several services at UCSF Health. Our survey 
identified 22 physicians and 19 pharmacists who have used PG in the past 12 months, 
another 48 physicians and 32 pharmacists who were interested in adopting PG in their 
services, and lastly, the contact information of 49 physicians and 33 pharmacists that were 
interested in discussing clinical PG with the authors. This work has given us the basis for 
planning the next stages of our endeavors to initiate and optimize clinical PG at UCSF 
Health. Given the exploratory nature of this study, these results are helpful for assessment of 
clinician needs, interest, and challenges that have hindered wide use of PG at UCSF Health. 
These finding have informed our subsequent plans for initiation and optimization of clinical 
PG practices at UCSF Health and we believe that such data can help other institutions with 
their plans in initiating or optimizing PG practices
In conclusion, as a first step, this qualitative approach for needs assessment was appropriate 
and sufficient for identifying clinicians and services interested in PG at UCSF Health. These 
results have set the foundation for next steps towards an organized approach to further PG 
integration as standard of care for our patients. While this quantitative method is imprecise 
and the results obtained are limited to practices in services surveyed at UCSF Health, this 
approach is sufficient to explore the interest and practice of clinicians in other institutions 
looking to initiate a clinical PG program.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow chart of the number of surveys sent, received, and completed by physicians and 
pharmacists.
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Table 1.
Summary of Survey Participants (N=135) and Responses
Physician Respondents (n=76) (%)
Pharmacist† Respondents 
(n=59) (%)
Number of years in practice
Less than 5 years 11 (14) 20 (34)
5–10 years 16 (21) 20 (34)
More than 10 years 49 (64) 19 (32)
Survey response rate 27% 50%
Medical specialty (response rate)
  Cardiology 9 (20) 9
  Infectious diseases 5 (ND‡) 12
  Neurology 4 (ND‡) 7
  Oncology 9 (47) 7
  Pain 11 (48) 9
  Primary care 16 (27) 18
  Psychiatry 14 (ND‡) 5
  Transplant 11 (35) 17
Currently using PG testing in practice 22 (29) 19 (32)
Interest in starting PG testing in practice 48 (63) 32 (54)
Currently not using PG and not interested in integrating PG 6 (8) 8 (14)
Clinicians indicating interest in discussing their interest in clinical 
PG with us 49 (64) 33 (56)
Observational studies sufficient evidence for PG testing 45 (59) 35 (59)
ND = not determined; PG = pharmacogenetics.
†
Response rate for pharmacists across medical specialties is not determined given that all pharmacists selected more than one clinical specialty in 
the survey.
‡Unable to calculate response rate because we did not know the number of physicians who received the survey.
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Table 4.
Barriers to PG Testing Identified by UCSF Health Physicians and Pharmacists Sorted From Highest to Lowest 
Number of Times Selected by Both Clinicians (i.e., Combined)
Barriers Physicians n=76 (%) Pharmacists n=59 (%) Combined N=135 (%)
Lack of established and clear guidelines/protocols for 
translating test results
51 (67) 41 (69) 92 (68)
Cost/payer’s restrictions on reimbursement for PG testing 48 (63) 32 (54) 80 (59)
Limited professional education in PG 43 (57) 37 (63) 80 (59)
Limited internal UCSF PG testing options 32 (42) 27 (46) 59 (44)
Ordering PG testing is not easy 36 (47) 22 (37) 58 (43)
Turnaround time on PG testing is not practical 21 (28) 33 (56) 54 (40)
Lack of a UCSF PG consultation service 26 (34) 23 (39) 49 (36)
Lack of point-of-care electronic clinical decision support to 
utilize PG tests
28 (37) 19 (32) 47 (34)
Limited scientific evidence linking test results to health 
outcomes
24 (32) 18 (31) 42 (31)
Diagnostic tests are not FDA-approved 13 (17) 6 (10) 19 (14)
There are no barriers for my practice/service. We are using 
the test
7 (9) 3 (5) 10 (7)
Patients do not want PG testing 1 (1) 0 (0) 1 (1)
FDA = Food and Drug Administration; PG = pharmacogenetic; UCSF = University of California, San Francisco.
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